Short Sellers Get More Selective on Big Biotech

24/7 Wall St.

DNAThe short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The June 15 short interest data have been compared with the previous figures, and overall, short interest in the selected stocks was mixed.

Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 9.67 million shares from the previous reading of 8.60 million. Shares closed Wednesday at $159.89, in a 52-week trading range of $114.93 to $173.60.

Biogen Inc. (NASDAQ: BIIB) saw its short interest increase slightly to 2.58 million shares from the previous 2.54 million. The company was slowly approaching the lower part of its short interest range from backā€¦

View original post 222 more words

Advertisements
Short Sellers Get More Selective on Big Biotech

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s